Ocugen, Inc. (NASDAQ:OCGN – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $9.00.
A number of equities analysts recently issued reports on OCGN shares. Oppenheimer began coverage on shares of Ocugen in a research note on Wednesday, March 11th. They issued an “outperform” rating and a $10.00 price target on the stock. Canaccord Genuity Group began coverage on shares of Ocugen in a report on Tuesday, March 17th. They issued a “buy” rating and a $12.00 target price for the company. Chardan Capital reiterated a “buy” rating and issued a $7.00 target price on shares of Ocugen in a research note on Thursday, March 5th. Wall Street Zen upgraded shares of Ocugen from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd.
Check Out Our Latest Research Report on Ocugen
More Ocugen News
- Positive Sentiment: Oppenheimer initiated coverage with an Outperform (Buy) rating and a $10 price target, calling Ocugen an emerging leader in gene therapy for blinding ocular disorders — a major analyst endorsement that can attract institutional interest. Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating
- Positive Sentiment: Canaccord Genuity initiated coverage with a Buy rating and $12 price target, highlighting three clinical-stage retinal programs and “interesting” early data — another bullish analyst view that supports higher upside expectations. Canaccord Initiates Coverage of Ocugen, Inc. (OCGN) with a Buy Rating and a $12 Price Target
- Positive Sentiment: Ocugen announced it gained $15 million in a prior registered direct offering, extending its cash runway into 2027 — reduces immediate financing pressure and lowers short-term insolvency risk. Ocugen Gains $15 Million, Extends Cash Runway to 2027
- Neutral Sentiment: Analyst and trade commentary outlined a pipeline calendar of 2026–2027 catalysts (pivotal data, filings across three programs) that could drive large swings — important for timing but binary in outcome. OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
- Neutral Sentiment: Multiple outlets summarized the new coverage notes (Canaccord/Oppenheimer), increasing visibility but duplicating the same catalyst-driven narrative. Ocugen (OCGN) Receives a New Rating from Canaccord Genuity
- Negative Sentiment: Zacks flagged rising cash burn and dilution risk as Ocugen advances late‑stage programs — investors should expect financing needs and potential share issuance if data or revenue don’t materialize. Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
- Negative Sentiment: Short-term market reaction showed a share decline and underperformance in recent session(s), reflecting the tug-of-war between bullish analyst targets and financing/data risks. Ocugen Inc. stock falls Wednesday, underperforms market
Ocugen Stock Down 8.9%
Shares of NASDAQ:OCGN opened at $2.04 on Tuesday. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 8.04. The stock has a fifty day simple moving average of $1.73 and a two-hundred day simple moving average of $1.51. Ocugen has a 12-month low of $0.56 and a 12-month high of $2.72. The stock has a market capitalization of $668.92 million, a price-to-earnings ratio of -8.87 and a beta of 2.75.
Ocugen (NASDAQ:OCGN – Get Free Report) last released its earnings results on Wednesday, March 4th. The company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06). Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18%.The firm had revenue of ($0.19) million for the quarter, compared to analysts’ expectations of $0.86 million. On average, research analysts anticipate that Ocugen will post -0.2 earnings per share for the current fiscal year.
Institutional Trading of Ocugen
A number of institutional investors and hedge funds have recently modified their holdings of the business. Cora Capital Advisors LLC raised its stake in shares of Ocugen by 27.5% in the fourth quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock worth $41,000 after purchasing an additional 6,500 shares during the last quarter. Jain Global LLC boosted its position in shares of Ocugen by 7.2% during the fourth quarter. Jain Global LLC now owns 114,690 shares of the company’s stock valued at $155,000 after buying an additional 7,686 shares during the last quarter. Lanham O Dell & Company Inc. boosted its position in shares of Ocugen by 7.7% during the third quarter. Lanham O Dell & Company Inc. now owns 140,000 shares of the company’s stock valued at $228,000 after buying an additional 10,000 shares during the last quarter. Procyon Advisors LLC increased its holdings in Ocugen by 5.5% in the 3rd quarter. Procyon Advisors LLC now owns 211,100 shares of the company’s stock worth $344,000 after buying an additional 11,000 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Ocugen by 56.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock worth $36,000 after buying an additional 13,326 shares in the last quarter. Institutional investors own 10.27% of the company’s stock.
Ocugen Company Profile
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.
In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.
Recommended Stories
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.
